RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028


Market Overview:

The global RNA interference (RNAi) drug delivery market size reached US$ 69.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 235.1 Billion by 2028, exhibiting a growth rate (CAGR) of 21.4% during 2023-2028.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global RNA interference (RNAi) drug delivery market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on application and technology.

Breakup by Application:

Infectious Disease
Cardiology
Oncology
Neurology
Ophthalmology
Urology
Metabolic Disorders
Others

Breakup by Technology:

Nanoparticle Drug Delivery
Pulmonary Drug Delivery
Nucleic Acid Drug Delivery
Aptamer Drug Delivery

Breakup by Region:

North America

United States
Canada

Asia Pacific

China
Japan
India
South Korea
Australia
Indonesia
Others

Europe

Germany
France
United Kingdom
Italy
Spain
Russia
Others

Latin America

Brazil
Mexico
Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc and Sirnaomics Inc.

Key Questions Answered in This Report:

How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
What are the key regional markets?
What is the breakup of the market based on the application?
What is the breakup of the market based on the technology?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
What is the degree of competition in the industry?


1 Preface
2 Scope and Methodology 
  2.1 Objectives of the Study
  2.2 Stakeholders
  2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
  2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
  2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
  4.1 Overview
  4.2 Key Industry Trends
5 Global RNA Interference (RNAi) Drug Delivery Market
  5.1 Market Overview
  5.2 Market Performance
  5.3 Impact of COVID-19
  5.4 Market Forecast
6 Market Breakup by Application
  6.1 Infectious Disease
6.1.1 Market Trends
6.1.2 Market Forecast
  6.2 Cardiology
6.2.1 Market Trends
6.2.2 Market Forecast
  6.3 Oncology
6.3.1 Market Trends
6.3.2 Market Forecast
  6.4 Neurology
6.4.1 Market Trends
6.4.2 Market Forecast
  6.5 Ophthalmology
6.5.1 Market Trends
6.5.2 Market Forecast
  6.6 Urology
6.6.1 Market Trends
6.6.2 Market Forecast
  6.7 Metabolic Disorders
6.7.1 Market Trends
6.7.2 Market Forecast
  6.8 Others
6.8.1 Market Trends
6.8.2 Market Forecast
7 Market Breakup by Technology
  7.1 Nanoparticle Drug Delivery
7.1.1 Market Trends
7.1.2 Market Forecast
  7.2 Pulmonary Drug Delivery
7.2.1 Market Trends
7.2.2 Market Forecast
  7.3 Nucleic Acid Drug Delivery
7.3.1 Market Trends
7.3.2 Market Forecast
  7.4 Aptamer Drug Delivery
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Region
  8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
  8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
  8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
  8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
  8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
  9.1 Overview
  9.2 Strengths
  9.3 Weaknesses
  9.4 Opportunities
  9.5 Threats
10  Value Chain Analysis
11  Porters Five Forces Analysis
  11.1 Overview
  11.2 Bargaining Power of Buyers
  11.3 Bargaining Power of Suppliers
  11.4 Degree of Competition
  11.5 Threat of New Entrants
  11.6 Threat of Substitutes
12  Price Analysis
13  Competitive Landscape
  13.1 Market Structure
  13.2 Key Players
  13.3 Profiles of Key Players
13.3.1 Alnylam Pharmaceuticals Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio 
13.3.1.3 Financials 
13.3.1.4 SWOT Analysis
13.3.2 Arrowhead Pharmaceuticals Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials 
13.3.3 CureVac AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio 
13.3.3.3 Financials
13.3.4 Dicerna Pharmaceuticals Inc.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio 
13.3.4.3 Financials
13.3.5 Gradalis Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio 
13.3.6 Ionis Pharmaceuticals Inc
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio 
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Merck & Co. Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials 
13.3.7.4 SWOT Analysis
13.3.8 Moderna Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio 
13.3.8.3 Financials 
13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.10 Silence Therapeutics Plc
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio 
13.3.10.3 Financials 
13.3.11 Sirnaomics Inc.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio 

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings